Eсulizumab in treatment of ANCA-associated vasculitis complicated with Covid-19. Clinical observations

Vasculitis associated with the antineutrophilic cytoplasmic antibodies (ANCA) is an autoimmune systemic severe, often life-threatening, disease characterized by necrotizing inflammation of small vessels. In 75-90% of cases of ANCA-associated vasculitis (AAV), a rapidly progressive pauci-immune necrotizing crescentic glomerulonephritis develops. Despite current treatment with high-dose glucocorticoids and either cyclophosphamide or rituximab, patients have a nine-fold increased mortality risk during the first year of disease compared with healthy subjects. This high mortality is attributed mainly to infections and vasculitis activity. Recent data suggest that the activation of the complement system, and in particular the alternative complement pathway, plays a significant role in the pathogenesis of AAV. It has been suggested that neutrophils primed by infection or pro-inflammatory cytokines release properdin, which activates an alternative complement cascade with cleavage of C5 into C5a and C5b. Anaphylatoxin C5a binds to receptors on the surface of neutrophils, enhancing their priming and activation and thus contributing to the inflammation. The randomized clinical trial showed that the selective C5a-receptor inhibitor avakopan was effective in the treatment of AAV. However, avacopan is currently not available in the everyday clinical practice. On the other hand, reports showing successful usage of monoclonal antibody against C5 eculizumab in severe AAV had been published. Here we present four cases of AAV complicated by COVID-19, for which conventional therapy with cyсlophosphamide could not be applied due to the particularly high risk of serious infectious complications, and eculizumab was used off-label by decision of the medical council and special commission. Taking this decision, we took into account data demonstrating the role of complement activation and, in particular, C5a in the pathogenesis of acute lung disease, induced by pathogenic viruses. Moreover, the successful usage of eculizumab in severe COVID-19 was reported recently. Thus, we sought to apply an approach aimed simultaneously at the pathogenetic mechanisms of both AAV and viral lung damage.

АНЦА-ассоциированный васкулит, комплемент, альтернативный путь комплемента, анафилатоксин С5а, COVID-19, пневмония, экулизумаб, ANCA-associated vasculitis, complement, alternative complement pathway, anaphylatoxin С5а, COVID-19, pneumonia, eculizumab

1. Jennette J.C., Falk R.J., Bacon P.A. et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65:1-11.

2. Jennette J.C., Falk R.J., Gasism A.H. Pathogenesis of antineutrophil cytoplasmic autoantibody vasculitis. Curr Opin Nephrol Hypertens. 2011; 20:263-270.

3. Фролова Н.Ф. Быстропрогрессирующий гломерулонефрит, ассоциированный с ANCA-васкулитом: клинико-морфологические варианты, лечение, прогноз. Дисс канд. Москва. 2017. 141 с.

4. Томилина Н.А. Бирюкова Л.С. Фролова Н.Ф. и соавт. Клинико-морфологическая характеристика и прогноз разных гистоморфологических вариантов быстропрогрессирующего гломерулонефрита, ассоциированного с АНЦА-васкулитом. Нефрология и диализ 2017; т. 19: №4: стр. 466-477.

5. Berden A.E., Ferrario F., Hagen E.C. et al. Histopathologic classification of ANCA-associated glomerulonephritis. J. Am. Soc. Nephrol. 2010; 21:1628-1636.

6. Franssen C.F., Stegman C.A., Kallenberg C.G. et al. Antiproteinase-3 and antimyeloperoxidase associated vasculitis. Kidney Int. 2000; 57:2195-2206.

7. Luqmani R., Suppiah R., Edwards C.J. et al. Mortality in Wegener’s granulomatosis: A bimodal pattern. Rheumatology (Oxford). 2011; 50:697-702.

8. Little M.A., Nightingale P., Verburgh C.A. et al. European Vasculitis Study (EUVAS) Group: Early mortality in systemic vasculitis: Relative contribution of adverse events and active vasculitis. Ann Rheum Dis. 2010; 69:1036-1043.

9. Jayne D. Evidence-based treatment of systemic vasculitis. Rheumatology (Oxford) 2000; 39: 585-595.

10. Koldingsnes W, Nossent H. Predictors of survival and organ damage in Wegener’s granulomatosis. Rheumatology (Oxford). 2002; 41:572-581.

11. Corral-Gudino L, Borao-Cengotita-Bengoa M, Del Pino-Montes J et al. Overall survival, renal survival and relapse in patients with microscopic polyangiitis: A systematic review of current evidence. Rheumatology (Oxford) 2011; 50:1414-1423.

12. Takala J. H., Kautiainen H., Finne P. et al. Wegener’s granulomatosis in Finland in 1981-2000: Risk of dialysis-dependent renal disease. Scand J Rheumatol. 2011; 40:283-288. Mohammad AJ, Segelmark M. A population-based study showing better renal prognosis for proteinase 3 antineutrophil cytoplasmic antibody (ANCA)-associated nephritis versus myeloperoxidase ANCA-associated nephritis. J Rheumatol. 2014; 41:1366-1373.

13. Jennette J.C., Wilkman A.S., Falk R.J. Anti-neutrophil cytoplasmic autoantibody associated glomerulonephritis and vasculitis. Am. J. Pathol. 1989; 135, 921-930.

14. Xiao H., Schreiber A., Heeringa P. et al. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am. J. Pathol. 2007; 170:52-64.

15. Huugen, D., van Esch, A., Xiao, H., еt al. Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice. Kidney Int. 2007; 71: 646-654.

16. Chen M., Jayne D.R., Zhao M.H. Complement in ANCA-associated vasculitis: mechanisms and implications for management. Nat. Rev. Nephrol. 2017; 13:359-367.

17. Quintana L.F., Kronbichler A., Blasco M. et al. ANCA associated vasculitis: The journey to complement-targeting therapies. Molecular Immunology. 2019; 112:394-398. https://doi.org/10.1016/j.molimm.2019.06.018

18. Xing G.Q., Chen M., Liu G. et al. Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis. J. Clin. Immunol. 2009; 29:282-291.

19. Scaglioni V., Scolnik M. Catoggio, L.J. et al. ANCA-associated pauci-immune glomerulonephritis: always pauci-immune? Clin. Exp. Rheumatol. 2017; 35(Suppl 103): 55-58.

20. Hilhorst, M., van Paassen, P., van Rie, H., et al. Complement in ANCA-associated glomerulonephritis. Nephrol. Dial. Transplant. 2017; 32:1302-1313. DOI:10.1093/ndt/gfv288

21. Gou S.J., Yuan J., Wang C., et al. Alternative complement pathway activation products in urine and kidneys of patients with ANCA-associated GN. Clin. J. Am. Soc. Nephrol. 2013; 8:1884-1891.

22. Gou, S.J., Yuan, J., Chen, M., et al. Circulating complement activation in patients with antineutrophil cytoplasmic antibody-associated vasculitis. Kidney Int. 2013, 83, 129-137.

23. Manenti L. Vaglio A., Gnappi E. et al. Association of serum C3 concentration and histologic signs of thrombotic microangiopathy with outcomes among patients with ANCA-associated renal vasculitis. Clin. J. Am. Soc. Nephrol. 2015; 10:2143-2151. DOI:10.2215/CJN.00120115

24. Fukui S., Iwamoto N., Umeda M. et al. Antineutrophilic cytoplasmic antibody-associated vasculitis with hypocomplementemia has a higher incidence of serious organ damage and a poor prognosis. Medicine. 2016; 95:37-44. DOI:10.1097/MD.0000000000004871

25. Deshayes S., Aouba A., Khoy K. et al. Hypocomplementemia is associated with worse renal survival in ANCA-positive granulomatosis with polyangiitis and microscopic polyangiitis. Plos One 2018; 13:e0195680.

26. Geetha D., Jefferson J.A. ANCA-associated vasculitis: Core Curriculum. AJKD. 2020; 75:124-137. https://doi.org/10.1053/j.ajkd.2019.04.031

27. Jayne D.R.W., Bruchfeld A.N., Harper L. et al. Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis. J.Am.Soc Nephrol. 2017; 28:2756-2767. https://doi.org/10.1681/asn.2016111179

28. Huizenga N., Zonozi R., Rosenthal J. et al. Treatment of aggressive antineutrophil cytoplasmic antibody-associated vasculitis with eculizumab. Kidney International Reports. 2020; 5:542-545. DOI: 10.1016/J.EKIR.2019.11.021

29. Manenti L., Urban M.L., Maritati F. et al. Complement blockade in ANCA-associated vasculitis: an index case, current concepts and future perspectives. Intern Emerg Med. 2017; 12:727-731. DOI:10.1007/s11739-017-1636-6

30. Diurno F., Numis F.G., Porta G. et al. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. Eur. Rev. Med. Pharmacol. Sci. 2020; 24:4040-4047.

31. Wang R., Xiao H., Guo R., Li Y., Shen B. The role of C5a in acute lung injury induced by highly pathogenic viral infections. Emerg Microbes Infect. 2015; 4:e28.

32. Gralinski L.E., Sheahan T.P., Morrison T.E. et al. Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. mBio. 2018; 9: e01753-18. https://doi.org/10.1128/mBio.01753-18.

33. Jiang Y., Zhao G., Song N. et al. Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV. Emerg Microbes Infect. 2018; 7:77. DOI 10.1038/s41426-018-0063-8

34. Campbell C.M., Kahwash R. Will Complement Inhibition be the New Target in Treating COVID-19 Related Systemic Thrombosis? Circulation. 2020; 141:1739-1741. DOI: 10.1161/CIRCULATIONAHA.120.047419

35. Magro C., Mulvey J.J., Berlin D., et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases Translational Research. 2020; 220:1-13. doi: https://doi.org/10.1016/j.trsl.2020.04.007

36. Diurno F., Numis F.G., Porta G. et al. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. European Review for Medical and Pharmacological Sciences. 2020; 24:4040-4047.